We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · September 15, 2016

Comparison of the Effectiveness of Adalimumab, Etanercept, and Ustekinumab in Psoriasis Patients

The British Journal of Dermatology


Additional Info

Disclosure statements are available on the authors' profiles:

The British Journal of Dermatology
Comparison of the One and 5-Years Effectiveness of Adalimumab, Etanercept and Ustekinumab in Psoriasis Patients in Daily Clinical Practice: Results From the Prospective BioCAPTURE Registry
Br J Dermatol 2016 Aug 31;[EPub Ahead of Print], J Zweegers, JM Groenewoud, JM van den Reek, ME Otero, PC van de Kerkhof, RJ Driessen, PP van Lümig, MD Njoo, PM Ossenkoppele, JM Mommers, MI Koetsier, WP Arnold, MP Andriessen, AL Kuijpers, MA Berends, W Kievit, EM de Jong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading